Model DP-4 Dry Powder Insufflator™

REFERENCES

Bot, A.I., Tarara, T.E., Smith, D.J., Bot, S.R., Woods, C.M., and Weers, J.G. (2000) Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res 17(3):275.

Codrons, B., Préat, V., and Vanbever, R. (2001) Optimization of systemic hPTH(1-34) delivery using inhalation dry powders. Poster, Belgian-Dutch Biopharm Soc Ann Meeting.

Hickey, A.J., Suarez, S., Bhat, M., O’Hara, P., Lalor, C.B., Atkins, K., Hopfer, R., and McMurray, D.N. (1998) Efficacy of rifampicin-poly (lactide-co-glycolide) microspheres in treating tuberculosis. Respiratory Drug Delivery VI II:201.

Meyer, K.B., Barron, M., Mumper, R., Rowland, A., and Szoka, F.C., Jr. (1995) Delivery of stabilized lipid-plasmid DNA complexes to the lung as dry powders and suspensions. Abstract, N Am Cystic Fibrosis Ann Conf.

Regal, J.F., and Larsen, C.P. (2001) Intratracheally instilled trimellitic anhydride dust causes both sensitization dependent and independent bronchoconstriction. Poster J29 (A47), Am Thoracic Soc Ann Conf.

Suarez, S., O’Hara, P., Kazantseva, M., Newcomer, C.E., Hopfer, R., McMurray, D.N., and Hickey, A.J. (2001) Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrobial Chemotherapy 48:431-434.

Suarez, S., Talton, J.D., and Hochhaus, G. (1998) Assessment of pulmonary selectivity of triamcinalone acetonide powders using an ex vivo receptor binding assay. Respiratory Drug Delivery VI II:425.

Talton, J.D., and Hochhaus, G. (1999) Plasma concentrations and pulmonary targeting of budesonide after intravenous and intratracheal administration in rats. Poster, Am Assoc Pharm Scientists Ann Meeting.

Talton, J.D., Suarez, S., and Hochhaus, G. (1998) Pulmonary targeting of intratracheal fluticasone propionate dry-powders vs. intravenous solution using an ex vivo receptor binding assay. Poster #1211, Am Assoc Pharm Scientists Ann Meeting.

Wang, L., Smith, D., Bot, S., Dellamary, L., Bloom, A., and Bot, A. (2002) Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J Clin Invest 110(8):1175-1184.